Modeling Long-term Vaccination Strategies With MenAfriVac in the African Meningitis Belt
| Autor: | Caroline Trotter, Andromachi Karachaliou, Andrew J. K. Conlan, Marie-Pierre Preziosi |
|---|---|
| Přispěvatelé: | Conlan, Andrew [0000-0002-2593-6353], Trotter, Caroline [0000-0003-4000-2708], Apollo - University of Cambridge Repository |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Microbiology (medical)
Adult Male Adolescent Population The Meningitis Vaccine Project: The Development Licensure Introduction and Impact of a New Group a Meningococcal Conjugate Vaccine for Africa Meningococcal Vaccines Meningococcal vaccine Meningitis Meningococcal medicine.disease_cause Young Adult Environmental health vaccine medicine Disease Transmission Infectious Humans education Child Aged Aged 80 and over education.field_of_study business.industry Neisseria meningitidis Meningitis Vaccine Project Vaccination mathematical modeling Age Factors Infant Newborn meningitis Infant Middle Aged Models Theoretical medicine.disease Virology 3. Good health Infectious Diseases Serologic and Safety Studies of a Group a Meningococcal Conjugate Vaccine Child Preschool Africa Female Seasons African meningitis belt business Meningitis MenAfriVac |
| Zdroj: | Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America |
| Popis: | The African meningitis belt suffers from frequent large epidemics of meningococcal meningitis. A novel vaccine against Neisseria meningitidis group A (MenA), the major cause of epidemic meningitis, was developed through the Meningitis Vaccine Project (MVP), manufactured by the Serum Institute of India, Ltd [1]. The vaccine, known as MenAfriVac, was first introduced into Burkina Faso, Mali, and Niger in 2010 in mass immunization campaigns targeting 1- to 29-year-olds. MenAfriVac continues to be rolled out across the region, and >217 million individuals have been immunized to date. These campaigns have been remarkably successful in the short term in reducing the incidence of meningitis and the prevalence of MenA carriage, as shown in Burkina Faso [2, 3] and Chad [4]. To ensure that this success continues, long-term immunization strategies are required to maintain population protection. Computational models have become an important tool for vaccine policy makers. By simulating the impact of a vaccine in silico, a wide range of vaccine strategies can be explored and the sensitivity of their predicted impact to structural and parameter uncertainty can be understood. Transmission dynamic models are essential to quantify both the direct and indirect (herd protection) effects of vaccination programs. For meningococcal infection, most transmission occurs between asymptomatic carriers, so any model attempting to capture the transmission dynamics of meningococci must essentially include the carrier state. This is especially relevant when considering the impact of MenAfriVac, given the evidence that MenA carriage is much reduced following MenAfriVac introduction [2, 4]. This is likely to give rise to large indirect vaccine effects, as seen with other conjugate vaccines [5]. Other key features of the epidemiology of MenA in the African meningitis belt must also be incorporated, which include the periodic but irregular nature of epidemics of varying size; the seasonality of meningitis with epidemics occurring in the dry season and dying out with the onset of the rains [6]; and the variation in disease risk [7] and carriage prevalence [8] by age. A range of transmission models for meningococcal infection has been developed [9–11]. Only 2 have specifically examined MenA in the African meningitis belt. Irving et al [12] explored the potential mechanisms underlying the striking epidemiology in this region, showing that the complex and irregular timing of epidemics could be explained by the interaction of temporary immunity conferred by carriage of the bacteria together with seasonal changes in the transmissibility of infection. Tartof et al [13] used a transmission model to investigate different strategies using MenAfriVac. Here we extend the transmission models of Irving et al [12] by addressing some of the limitations (such as the lack of age structure and wide parameter space considered), and incorporating vaccination. We utilize recently available MenA/MenAfriVac specific parameters and apply the model to investigate appropriate policy options for the sustained use of MenAfriVac. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|